Key result
LA-FINDRISC detects glucose alterations with 91% sensitivity versus FINDRISC in young women with breast cancer.
Why the study?
Breast cancer patients have a high prevalence of metabolic alterations, but the effectiveness of FINDRISC and LA-FINDRISC questionnaires to identify cardiometabolic risk in young women with breast cancer had not been evaluated.
Are the FINDRISC and LA-FINDRISC questionnaires effective in identifying cardiometabolic risk in young women with localized breast cancer?
Cross-Sectional (n=52)
Are the FINDRISC and LA-FINDRISC questionnaires effective in identifying cardiometabolic risk in young women with localized breast cancer?
The FINDRISC and LA-FINDRISC questionnaires are useful and easy-to-apply clinical tools for identifying cardiometabolic risk in young women with breast cancer, despite having lower sensitivity than biochemical criteria.
Answers are grounded in this paper and cite their sources.
May support glucose screening in young breast cancer patients; leaves open prospective validation against biochemical criteria.
Introduction: Background: breast cancer patients present a high prevalence of other chronic diseases and metabolic alterations, including overweight at diagnosis of cancer. This risk also increases after oncology treatment and is a current concern for Latin American countries. Currently, the use of different criteria to identify cardiometabolic risk has been widely applied, considering anthropometric, biochemical and clinical parameters. Additionally, the development of validated screening tools, such as the FINDRISC and LA-FINDRISC, has been considered useful for clinicians to assess metabolic risk in different populations. Objective: the present study aims to evaluate the effectiveness of the FINDRISC and LA-FINDRISC questionnaires to identify cardiometabolic risk in young women with breast cancer. Material and methods: a total of 52 participants were included. Results: a sensitivity of 83 % and specificity of 89 % were found for FINDRISC, and a sensitivity of 91 % and specificity of 74 % for LA-FINDRISC to detect alterations in glucose metabolism. Conclusions: both questionnaires showed lower sensitivity than the international standard criteria for metabolic syndrome, which consider biochemical parameters to assess metabolic alterations. However, these tools and anthropometric measures are useful and easy to apply for clinicians to identify, prevent and treat potential comorbidities associated to cardiometabolic risk in young women with breast cancer.
No takes yet. Share an insight, caveat, or question.
Becerra-Herrera et al. (2025) conducted a cross-sectional in localized breast cancer (n=52). FINDRISC and LA-FINDRISC questionnaires vs. international standard criteria for metabolic syndrome was evaluated on detection of alterations in glucose metabolism. The LA-FINDRISC questionnaire detected alterations in glucose metabolism with 91% sensitivity and 74% specificity, compared to 83% and 89% for FINDRISC, in young women with breast cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: